Compare PRE & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | XFOR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.8M | 323.5M |
| IPO Year | N/A | N/A |
| Metric | PRE | XFOR |
|---|---|---|
| Price | $19.38 | $3.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $32.00 | $28.50 |
| AVG Volume (30 Days) | 255.5K | ★ 338.8K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $77,079,000.00 | $33,979,000.00 |
| Revenue This Year | $219.28 | $1,266.01 |
| Revenue Next Year | $124.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 201.54 | ★ 2925.74 |
| 52 Week Low | $3.10 | $1.35 |
| 52 Week High | $20.89 | $20.10 |
| Indicator | PRE | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 57.11 |
| Support Level | $15.14 | $3.58 |
| Resistance Level | $20.89 | $3.74 |
| Average True Range (ATR) | 1.38 | 0.17 |
| MACD | 0.21 | 0.02 |
| Stochastic Oscillator | 77.70 | 95.45 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.